Liver CancerIRENCT02333773
Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli
A study testing Irreversible electroporation (IRE) in people with Liver Cancer, run by Fuda Cancer Hospital, Guangzhou at 1 site in China.
Trial summary
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Liver Cancer
- What is being tested?
- Irreversible electroporation (IRE)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2015to 1 Jan 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Liver cancer diagnosed by positive biopsy or non-invasive criteria,
- Liver cancer with Portal venous tumor emboli,
- Not suitable for surgical resection or transplantation,
- Child-Pugh class A,B
- Eastern Cooperative Oncology Group (ECOG) score of 0-1,
- A prothrombin time ratio > 50%,
Show all 10Show fewer
- Platelet count > 80x10^9/L,
- Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
- Able to comprehend and willing to sign the written informed consent form (ICF),
- Have a life expectancy of at least 3 months.
Who cannot join
- Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
- Any active implanted device (eg Pacemaker),
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
- Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
- Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
Read the detailed description
By enrolling patients with unresectable Portal venous tumor emboli adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous or intraoperative IRE for unresectable Portal venous tumor emboli.
- Conditions
- Liver Cancer
- Being tested
- Irreversible electroporation (IRE)
- Keywords
- irreversible electroporation, Portal venous tumor emboli
- Medical subject headings
- Liver Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Irreversible electroporation (IRE)Procedure or surgery
Also called NanoKnife
Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
| Study group | Role | What they receive |
|---|---|---|
| Group A | Experimental | irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli Receives: Procedure: Irreversible electroporation (IRE) |
| Group B | Experimental | irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli Receives: Procedure: Irreversible electroporation (IRE) |
| Group C | Experimental | irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli Receives: Procedure: Irreversible electroporation (IRE) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety (adverse effects)
adverse effects
Measured: 6 month
Secondary outcomes (4)
Efficacy (percentage of lesions that show no sign of recurrence 12 months after IRE)
The primary objective of this project is to evaluate the efficacy (percentage of lesions that show no sign of recurrence 12 months after IRE）
Measured: 12 months
Voltage (A minimum and maximum range of voltage for safe and effective IRE)
A minimum and maximum range of voltage for safe and effective IRE will be analyzed for optimal choice.
Measured: 3 months
Progress free disease (PFS)
Patients will be followed for 12 months after IRE for PFS assessing.
Measured: 12 months
Overall survival (OS)
Patients will be followed for 36 months after IRE for OS analyzed.
Measured: 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2015 (estimated)
- Study start1 Jan 2015
- Primary completion1 Dec 2020
- Study completion1 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fuda Cancer Hospital, Guangzhou
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lizhi Niu, PHD, Study chair, Fuda Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02333773
- Sponsor's protocol ID
- ZhangZhikai-IRE-01
- Acronym
- IRE
- Status last verified
- May 2019
- First submitted
- 6 Jan 2015
- Last updated
- 5 Sep 2021
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial
- ClinicalTrials.gov ID
- NCT02333773
- Acronym / sponsor ID
- IRE / ZhangZhikai-IRE-01
- Conditions
- Liver Cancer
- Keywords
- irreversible electroporation, Portal venous tumor emboli
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Fuda Cancer Hospital, GuangzhouUniversity, hospital or other
- Study start
- 1 Jan 2015 (actual)
- Primary completion
- 1 Dec 2020 (actual)
- Study completion
- 1 Jan 2021 (actual)
- First posted
- 7 Jan 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.
Detailed description
By enrolling patients with unresectable Portal venous tumor emboli adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous or intraoperative IRE for unresectable Portal venous tumor emboli.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group A | Experimental | Procedure: Irreversible electroporation (IRE)irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli |
| Group B | Experimental | Procedure: Irreversible electroporation (IRE)irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli |
| Group C | Experimental | Procedure: Irreversible electroporation (IRE)irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (10 listed)
- Liver cancer diagnosed by positive biopsy or non-invasive criteria,
- Liver cancer with Portal venous tumor emboli,
- Not suitable for surgical resection or transplantation,
- Child-Pugh class A,B
- Eastern Cooperative Oncology Group (ECOG) score of 0-1,
Key exclusion criteria (5 listed)
- Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
- Any active implanted device (eg Pacemaker),
- Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
- Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
- Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Irreversible electroporation (IRE)Also: NanoKnifeIrreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT. | Procedure or surgery | Group A, Group B, Group C |
Primary outcome
Safety (adverse effects)
Time frame: 6 month
adverse effects
4 secondary outcomes
Efficacy (percentage of lesions that show no sign of recurrence 12 months after IRE)
Time frame: 12 months
Voltage (A minimum and maximum range of voltage for safe and effective IRE)
Time frame: 3 months
Progress free disease (PFS)
Time frame: 12 months
Overall survival (OS)
Time frame: 36 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2021.
Related trials for Liver Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lizhi Niu, PHD study chair
Fuda Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Irreversible electroporation (IRE) in people with Liver Cancer, run by Fuda Cancer Hospital, Guangzhou at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety (adverse effects) (time frame: 6 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2021.